Newsfeeds Archive - Spark Newswire

1 minute read

NextCure To Present Phase 1b Data On NC410 And Pembrolizumab Combination at ASCO 2024 June 1, 2024

May 30, 4:43 PM

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a

NXTC

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

February 16, 5:31 PM

Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) shares increased by 13.3% to $0.37 during Friday’s after-market session. The market value of…

ANVS

4 minute read

Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Avi Kapoor

December 14, 1:56 PM

Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.

1 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

December 14, 1:32 PM

Gainers TriSalus Life Sciences (NASDAQ:TLSI) stock moved upwards by 38.3% to $8.23 during Thursday’s regular session. The market…

APLS

3 minute read

US Stocks Higher; Initial Jobless Claims Fall To 202,000

By Avi Kapoor

December 14, 10:40 AM

U.S. stocks traded higher this morning, following the release of economic reports on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 37,180.82 while the NASDAQ rose 0.60% to 14,822.95. The S&P 500 also rose, gaining, 0.50% to 4,730.68.

ASYS

1 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

December 14, 9:07 AM

Gainers Reshape Lifesciences (NASDAQ:RSLS) stock increased by 22.3% to $0.47 during Thursday’s pre-market session. The market value of…

AHG

1 minute read

News

NextCure’s Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

By Benzinga Newsdesk

October 17, 8:09 AM

NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today

NXTC

2 minute read

NextCure Presents Preclinical Data On NC181, A Novel Therapeutic Candidate Targeting ApoE4, For The Treatment Of Alzheimer’s Disease

By Happy Mohamed

September 26, 4:12 PM

Data presented at the 2023 Cambridge Health Tech Institute's 2nd Annual Neurodegeneration Targets Conference in Boston, MA In preclinical testing, NC181 demonstrated amyloid clearance, prevention of amyloid

NXTC

2 minute read

NextCure and Nordic Bioscience Publish Review Article On The Regulation Of Tumor Immunity By Tumor Collagen

By Happy Mohamed

September 7, 4:22 PM

NXTC

2 minute read

NextCure Announces Preclinical Data Demonstrate Potential Application Of Anti-Siglec-15 Treatment In Bone Disease

By Happy Mohamed

September 5, 4:21 PM

Data Presented at the 2023 Military Health System Research Symposium show activity in animal model of acute spinal cord injury-induced immobilization BELTSVILLE, Md., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NextCure,

NXTC